Eli Lilly acquired global rights to MeiraGTx’s AAV‑AIPL1 gene therapy for Leber congenital amaurosis 4 (LCA4) for $75 million up front. The program is on track for U.S. and European regulatory submissions, and the transaction adds a late‑stage ophthalmic gene therapy to Lilly’s growing genetic‑medicine portfolio. The purchase follows Lilly’s recent genetic-medicine deals and reflects a strategic push into rare retinal disorders. Lilly gains global development and commercialization responsibilities while MeiraGTx receives near-term funding to advance its pipeline.